New pill could clear psoriasis in weeks
NCT ID NCT07234591
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Skin Disease Hospital
RECRUITINGShanghai, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TYK2 inhibitor
What this could lead to
If it works, this could provide a new oral treatment option for people with moderate to severe plaque psoriasis.
What could go wrong
This is an early-stage trial with only 140 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.